An Open-Label Study to Assess Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect (PBA) in Dementia, Stroke and Traumatic Brain Injury: PRISM II Combined Cohort Results for Patients Aged ≥65 Years

2016 ◽  
Vol 24 (3) ◽  
pp. S146-S147 ◽  
Author(s):  
Flora Hammond ◽  
David N. Alexander ◽  
Andrew J. Cutler ◽  
Stephen D'Amico ◽  
Rachelle S. Doody ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Pseudobulbar Affect

scholarly journals PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

BMC Neurology ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Flora M. Hammond ◽  
David N. Alexander ◽  
Andrew J. Cutler ◽  
Stephen D’Amico ◽  
Rachelle S. Doody ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Pseudobulbar Affect

scholarly journals Dextromethorphan-quinidine is helpful for pseudobulbar affect disorder in stroke patients

2021 ◽  
Vol 7 (2) ◽  
Author(s):  
Michael Francis ◽  
Mira Hamame ◽  
Mariam Nasrallah ◽  
Alison Nesbitt ◽  
James P. Meza
Keyword(s):  
Traumatic Brain Injury ◽  
Informed Consent ◽  
Brain Injury ◽  
Stroke Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Pseudobulbar Affect

An informed consent article using Hammond FM, Alexander DN, Cutler AJ, et al. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology. 2016;16:89. https://doi.org/10.1186/s12883-016-0609-0 for a patient with pseudobulbar affect following stroke.

Open-label study of donepezil in traumatic brain injury

2001 ◽  
Vol 82 (7) ◽  
pp. 896-901 ◽  
Author(s):  
Cheryl A. Masanic ◽  
Mark T. Bayley ◽  
Robert vanReekum ◽  
Martine Simard
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

An open-label study of citalopram for major depression following traumatic brain injury

2008 ◽  
Vol 22 (8) ◽  
pp. 860-864 ◽  
Author(s):  
MJ Rapoport ◽  
F. Chan ◽  
K. Lanctot ◽  
N. Herrmann ◽  
S. McCullagh ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Major Depression ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results

CNS Spectrums ◽  
2015 ◽  
Vol 21 (6) ◽  
pp. 450-459 ◽  
Author(s):  
Rachelle S. Doody ◽  
Stephen D’Amico ◽  
Andrew J. Cutler ◽  
Charles S. Davis ◽  
Paul Shin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Primary Outcome ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Pseudobulbar Affect ◽  
Secondary Outcomes ◽  
Global Impression Of Change ◽  
Lateral Sclerosis

BackgroundDextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness and tolerability for PBA secondary to dementia, stroke, or traumatic brain injury; dementia cohort results are reported.MethodsThis was an open-label, multicenter, 90 day trial; patients received DM/Q 20/10 mg twice daily. Primary outcome was change in Center for Neurologic Study–Lability Scale (CNS-LS) score. Secondary outcomes included PBA episode count and Clinical and Patient/Caregiver Global Impression of Change scores with respect to PBA (CGI-C/PGI-C).Results134 patients were treated. CNS-LS improved by a mean (SD) of 7.2 (6.0) points at Day 90/Endpoint (P<.001) vs. baseline. PBA episodes were reduced 67.7% (P<.001) vs. baseline; global measures showed 77.5% CGI-C and 76.5% PGI-C “much”/”very much” improved. Adverse events included headache (7.5%), urinary tract infection (4.5%), and diarrhea (3.7%); few patients dropped out for adverse events (10.4%).ConclusionsDM/Q significantly reduced PBA symptoms in patients with dementia; reported adverse events were consistent with the known safety profile of DM/Q.Trial Registrationclinicaltrials.gov identifier: NCT01799941.

Sign in / Sign up

Export Citation Format

Share Document